NVS Stock Analysis: Buy, Sell, or Hold?
NVS - Novartis AG
$159.90
5.76 (3.74%)
▲
5d:
+3.08%
30d:
+11.44%
90d:
+3.11%
BUY
MODERATE Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Jul 16, 2026
12d
Get Alerted When NVS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: NVS shows positive signals but monitor for confirmation. Market pricing in 1.5% growth. Moderate conviction.
💡 BUY OPPORTUNITY: NVS shows positive signals but monitor for confirmation. Market pricing in 1.5% growth. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$226.53
Based on 8.2% avg growth
INTRINSIC VALUE TODAY
$140.66
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 15.5x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: NVS is currently trading at $159.90, which is considered extended relative to its 30-day fair value range of $147.11 to $155.06. The stock's valuation (Forward PE: 16.2) is in line with its historical norms (15.5). At these levels, the market is pricing in 1.5% annual earnings growth.
Technical Outlook: Technically, NVS is in a downtrend. The price is approaching resistance at $160.57. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 3.7% recently.
Market Sentiment: NVS has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, NVS is in a downtrend. The price is approaching resistance at $160.57. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 3.7% recently.
Market Sentiment: NVS has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$147.11 -
$155.06
Company Quality Score
59/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
65.2%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.7%)
- NEUTRAL: Near Wall St target ($154.56)
- BULLISH: Expecting earnings turnaround to 1.5% growth with -0.7% revenue growth
Trading Range Analysis
30-Day Trading Range
$147.11 -
$155.06
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$146.60
Resistance Level
$160.57
Current Trend
Downtrend
Technical data as of
Jul 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
16.16
Wall Street Target
$154.57
(-3.3%)
Revenue Growth (YoY)
-0.7%
Earnings Growth (YoY)
-9.3%
Profit Margin
23.9%
Valuation Premium vs History
+1.5% premium
PE vs Historical
16.2 vs 15.5
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+1.5%
(market-implied from PE analysis)
1-Year Target
$162.30
(+2%)
2-Year Target
$164.73
(+3%)
3-Year Target
$167.20
(+5%)
3-Yr Target (if PE normalizes)
(PE: 16→16)
PE COMPRESSION
$160.40
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.8, Growth: 12.3%)
$305.12
(+91%)
Base:
(SPY PE: 16.2, Growth: 12.3%)
$226.36
(+42%)
Bear:
(PE: 13.7, Growth: 12.3%)
$192.40
(+20%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (22x PE), but valuation improves significantly next year (16x PE) as earnings recover.
Trailing PE: 22.08 | Current EPS (TTM): $6.98
Bull Case
$240.39
(+50%)
Analyst growth 41.8%, PE expands to 24.3
Base Case
$218.54
(+37%)
Market implied 41.8%, PE stable at 22.1
Bear Case
$104.82
(-34%)
Severe decline -20.0%, PE contracts to 18.8
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: July 03, 2026 6:25 PM ET
Data refreshes hourly during market hours. Next update: 7:25 PM
Data refreshes hourly during market hours. Next update: 7:25 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NVS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - General Stocks
Top-rated stocks in Drug Manufacturers - General by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LLY
Eli Lilly and Company |
STRONG BUY
31 analysts |
$1223 | 61 BUY |
|
GILD
Gilead Sciences Inc |
BUY
30 analysts |
$158 | 67 BUY |
|
AMGN
Amgen Inc |
HOLD
32 analysts |
$353 | 69 BUY |
|
BIIB
Biogen Inc |
HOLD
37 analysts |
$220 | 67 BUY |
|
ABBV
AbbVie Inc |
BUY
28 analysts |
$254 | 60 HOLD |
